GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eisai Co Ltd (FRA:EIIA) » Definitions » EV-to-FCF

Eisai Co (FRA:EIIA) EV-to-FCF : 141.08 (As of Dec. 14, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Eisai Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Eisai Co's Enterprise Value is €6,889 Mil. Eisai Co's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was €49 Mil. Therefore, Eisai Co's EV-to-FCF for today is 141.08.

The historical rank and industry rank for Eisai Co's EV-to-FCF or its related term are showing as below:

FRA:EIIA' s EV-to-FCF Range Over the Past 10 Years
Min: -290.87   Med: 9.01   Max: 351.11
Current: 159.79

During the past 13 years, the highest EV-to-FCF of Eisai Co was 351.11. The lowest was -290.87. And the median was 9.01.

FRA:EIIA's EV-to-FCF is ranked worse than
89.45% of 550 companies
in the Drug Manufacturers industry
Industry Median: 25.795 vs FRA:EIIA: 159.79

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-14), Eisai Co's stock price is €6.45. Eisai Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €0.220. Therefore, Eisai Co's PE Ratio (TTM) for today is 29.32.


Eisai Co EV-to-FCF Historical Data

The historical data trend for Eisai Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eisai Co EV-to-FCF Chart

Eisai Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.56 55.80 18.58 -55.96 53.21

Eisai Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 109.68 53.99 53.21 135.40 201.08

Competitive Comparison of Eisai Co's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eisai Co's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eisai Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Eisai Co's EV-to-FCF falls into.



Eisai Co EV-to-FCF Calculation

Eisai Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=6888.662/48.827
=141.08

Eisai Co's current Enterprise Value is €6,889 Mil.
Eisai Co's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eisai Co  (FRA:EIIA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Eisai Co's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=6.45/0.220
=29.32

Eisai Co's share price for today is €6.45.
Eisai Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.220.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Eisai Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Eisai Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Eisai Co Business Description

Address
4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.

Eisai Co Headlines

No Headlines